Raymond James Financial Services Advisors Inc. lifted its position in shares of SAGE Therapeutics Inc (NASDAQ:SAGE) by 93.6% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 4,774 shares of the biopharmaceutical company’s stock after buying an additional 2,308 shares during the period. Raymond James Financial Services Advisors Inc.’s holdings in SAGE Therapeutics were worth $747,000 at the end of the most recent quarter.

Several other hedge funds have also recently bought and sold shares of SAGE. Allianz Asset Management GmbH raised its holdings in SAGE Therapeutics by 962.4% during the first quarter. Allianz Asset Management GmbH now owns 44,474 shares of the biopharmaceutical company’s stock worth $7,163,000 after acquiring an additional 40,288 shares in the last quarter. UBS Group AG raised its holdings in SAGE Therapeutics by 242.6% during the first quarter. UBS Group AG now owns 23,493 shares of the biopharmaceutical company’s stock worth $3,785,000 after acquiring an additional 16,636 shares in the last quarter. Swiss National Bank raised its holdings in SAGE Therapeutics by 19.8% during the first quarter. Swiss National Bank now owns 79,400 shares of the biopharmaceutical company’s stock worth $12,789,000 after acquiring an additional 13,100 shares in the last quarter. Northern Trust Corp raised its holdings in SAGE Therapeutics by 11.1% during the first quarter. Northern Trust Corp now owns 493,595 shares of the biopharmaceutical company’s stock worth $79,503,000 after acquiring an additional 49,437 shares in the last quarter. Finally, Millennium Management LLC raised its holdings in SAGE Therapeutics by 103.5% during the first quarter. Millennium Management LLC now owns 52,592 shares of the biopharmaceutical company’s stock worth $8,471,000 after acquiring an additional 26,747 shares in the last quarter.

NASDAQ:SAGE opened at $158.48 on Wednesday. The company has a market capitalization of $7.18 billion, a price-to-earnings ratio of -22.35 and a beta of 2.88. SAGE Therapeutics Inc has a 12-month low of $59.57 and a 12-month high of $195.97.

SAGE Therapeutics (NASDAQ:SAGE) last posted its earnings results on Tuesday, August 7th. The biopharmaceutical company reported ($0.36) EPS for the quarter, beating the consensus estimate of ($1.84) by $1.48. The firm had revenue of $90.00 million during the quarter. equities research analysts forecast that SAGE Therapeutics Inc will post -7.42 EPS for the current fiscal year.

SAGE has been the topic of several analyst reports. Cowen reiterated a “buy” rating and set a $207.00 target price on shares of SAGE Therapeutics in a report on Thursday, June 14th. BidaskClub lowered SAGE Therapeutics from a “sell” rating to a “strong sell” rating in a report on Friday, July 27th. Canaccord Genuity reiterated a “buy” rating and set a $210.00 target price on shares of SAGE Therapeutics in a report on Thursday, May 3rd. Morgan Stanley upped their price objective on SAGE Therapeutics from $225.00 to $228.00 and gave the company an “overweight” rating in a research note on Friday, July 13th. Finally, ValuEngine upgraded SAGE Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, May 2nd. Two equities research analysts have rated the stock with a sell rating, fifteen have given a buy rating and one has given a strong buy rating to the stock. SAGE Therapeutics presently has an average rating of “Buy” and an average target price of $199.19.

SAGE Therapeutics Company Profile

Sage Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel medicines to treat central nervous system disorders. Its lead product candidate comprises brexanolone, a proprietary intravenous formulation of allopregnanolone that has completed III clinical trials for the treatment of post-partum depression (PPD).

Featured Article: How Do You Make Money With Penny Stocks?

Institutional Ownership by Quarter for SAGE Therapeutics (NASDAQ:SAGE)

Receive News & Ratings for SAGE Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SAGE Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.